Pulling SEC filings + quote and writing the call…
| Fiscal year | FY2024 | FY2025 | FY2026 |
|---|---|---|---|
| Revenue | $2.47B | $2.71B | $3.10B |
| Revenue growth | — | 10.0% | 14.3% |
| Gross profit | $1.44B | $1.53B | $1.68B |
| Gross margin | 58.2% | 56.3% | 54.2% |
| Operating income | -$69.0M | -$146M | -$190M |
| Operating margin | -2.8% | -5.4% | -6.1% |
| Net income | -$112M | -$213M | -$333M |
| Net margin | -4.5% | -7.8% | -10.7% |
| EPS (diluted) | -$0.44 | -$0.84 | -$1.30 |
| Fiscal year | FY2024 | FY2025 | FY2026 |
|---|---|---|---|
| Operating cash flow | $41.0M | $140M | -$197M |
| Capital expenditures | $148M | $193M | $223M |
| Free cash flow | -$107M | -$53.0M | -$420M |
| Fiscal year | FY2024 | FY2025 | FY2026 |
|---|---|---|---|
| Cash & equivalents | $54.0M | $11.0M | $298M |
| Total assets | — | $4.20B | $4.63B |
| Total liabilities | — | $871M | $1.02B |
| Shareholders' equity | $3.45B | $3.33B | $3.61B |
| Retained earnings | — | $0.00 | -$116M |
| Shares (wtd avg diluted) | 253M | 253M | 257M |
Every figure is extracted from MiniMed Group, Inc.’s annual reports as filed with the SEC (XBRL company facts) — no third-party estimates. Fiscal years are labeled by period end; filers occasionally re-tag concepts, so a sparse cell means the company didn’t report that concept for that year. Free cash flow = operating cash flow − capital expenditures.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.